ADVFN US – Market Content Editor
-
Virtuix Expands Defense Business with U.S. Marine Corps Counter-Drone Training Program
Virtuix Holdings (NASDAQ:VTIX) announced that its Omni One full-body movement platform has been integrated into a next-generation counter-drone training simulator that will be evaluated by the U.S. Marine Corps, further expanding the company’s presence in the defense training market. Key Investor Takeaways Why VTIX Stock Is in Focus Virtuix announced that its Omni One movement…
-
Travelzoo Reports Q2 2026 Loss as Membership Strategy Weighs on Near-Term Results
Travelzoo (NASDAQ:TZOO) reported a second-quarter 2026 loss as geopolitical uncertainty and continued investment in its paid membership strategy weighed on revenue and profitability, while management maintained expectations for revenue growth in the second half of the year. Key Investor Takeaways Why TZOO Stock Is in Focus Travelzoo reported second-quarter revenue of $23.2 million, down 3%…
-
SunPower Reports Q2 2026 Results as Revenue Falls, Targets Sharp Q3 Recovery
SunPower Inc. (NASDAQ:SPWR) reported weaker second-quarter 2026 results as delayed residential solar installations weighed on revenue, while management outlined operational changes and cost reductions aimed at significantly improving profitability in the third quarter. Key Investor Takeaways Why SPWR Stock Is in Focus SunPower reported second-quarter revenue of $56.0 million, down from $72.8 million in the…
-
Itron Reports Q2 Earnings and Raises Full-Year 2026 EPS Outlook
Itron, Inc. (NASDAQ:ITRI) reported second-quarter 2026 results with lower revenue but record gross margins, higher adjusted EBITDA, and increased its full-year earnings outlook, reflecting continued operational improvements despite softer project timing. Key Investor Takeaways Why ITRI Stock Is in Focus Itron reported second-quarter revenue of $563 million, down 7% from the prior year as lower…
-
Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales Guidance
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported strong second-quarter 2026 financial results, raised its full-year ARCALYST sales guidance, and advanced its cardiovascular pipeline with the Phase 3 launch of KPL-387 for recurrent pericarditis. Key Investor Takeaways Why KNSA Stock Is in Focus Kiniksa delivered second-quarter revenue of $243.6 million, up from $156.8 million in the prior-year period, driven…
-
Onfolio Pursues Strategic Alternatives to Reshape Portfolio and Drive Shareholder Value
Onfolio Holdings (NASDAQ:ONFO) announced it is actively pursuing strategic alternatives, including acquisitions, transformational transactions, and asset divestitures, as part of a broader effort to strengthen its portfolio and enhance long-term shareholder value. Key Investor Takeaways Why ONFO Stock Is in Focus Onfolio announced that it is actively reviewing a range of strategic initiatives designed to…
-
A.I.S. Resources Secures New Brunswick Drilling Permit and Begins IOCG Exploration Program
A.I.S. Resources Limited (USOTC:AISSF) has received its first drilling permit for the Saint John project in New Brunswick, allowing the company to launch its Phase 1 exploration program targeting iron oxide-copper-gold (IOCG) prospects. Key Investor Takeaways Why AISSF Stock Is in Focus A.I.S. Resources announced that it has received the first required drilling permits from…
-
IDEXX Releases 2025 Corporate Responsibility Report Highlighting Innovation and Sustainability Progress
IDEXX Laboratories (NASDAQ:IDXX) released its 2025 Corporate Responsibility Report, outlining progress across innovation, workforce development, and environmental initiatives that support the company’s long-term growth strategy. Key Investor Takeaways Why IDXX Stock Is in Focus IDEXX released its latest Corporate Responsibility Report, detailing progress against a range of operational, innovation, and sustainability goals during 2025. On…
-
Repligen Reports Q2 Revenue Growth and Raises Full-Year 2026 Guidance
Repligen Corporation (NASDAQ:RGEN) reported double-digit second-quarter revenue growth and increased its full-year 2026 financial guidance, citing strong order momentum and continued market outperformance while highlighting its pending acquisition of BioLife Solutions. Key Investor Takeaways Why RGEN Stock Is in Focus Repligen reported second-quarter revenue of $204 million, up 12% from a year earlier, while delivering…
-
ICON Announces Multi-Year Anthropic Collaboration to Expand AI Across Clinical Trials
ICON plc (NASDAQ:ICLR) has entered a multi-year collaboration with Anthropic to integrate Claude’s AI capabilities across the clinical trial lifecycle, aiming to improve study planning, protocol design, operational efficiency, and trial execution through its Orbis AI platform. Key Investor Takeaways Why ICLR Stock Is in Focus ICON announced a strategic multi-year collaboration with Anthropic to…